Technische Universität Dresden
Clinical trials sponsored by Technische Universität Dresden, explained in plain language.
-
New drug cocktail aims to tame rare lung cancer
Disease control Not yet recruitingThis study tests whether adding a new drug, obrixtamig, to standard chemotherapy can help people with a rare and aggressive lung cancer called large-cell neuroendocrine carcinoma (LCNEC). The trial will include 75 adults with advanced LCNEC that cannot be cured by surgery. Resear…
Phase: PHASE2 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New trial aims to find safer chemo for stem cell transplants in leukemia patients
Disease control Not yet recruitingThis study tests two chemotherapy drugs, treosulfan and melphalan, given before a stem cell transplant in 220 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to see which drug works better at helping patients survive longer with fewer side …
Phase: PHASE2 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Jun 26, 2026 12:47 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Not yet recruitingThis study is a registry that will collect medical information and blood samples from 500 adults with myelodysplastic syndromes (MDS) and related conditions. The goal is to learn more about how these diseases develop and progress over time. Participants will not receive any exper…
Sponsor: Technische Universität Dresden • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Lung cancer immune markers under the microscope
Knowledge-focused Not yet recruitingThis observational study aims to understand how the immune system and tumor markers relate to treatment response in 500 people with advanced non-small cell lung cancer. Participants will provide tumor samples before and during immunochemotherapy. The study does not test any new d…
Sponsor: Technische Universität Dresden • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:25 UTC